| Source: |
| Type: |
| Tumor cell proliferation is a key characteristic of cancer. It refers to the rapid and uncontrolled growth of cells that can lead to the formation of tumors. |
| 5333- | TFdiG, | Theaflavin-3,3′-Digallate Plays a ROS-Mediated Dual Role in Ferroptosis and Apoptosis via the MAPK Pathway in Human Osteosarcoma Cell Lines and Xenografts |
| - | vitro+vivo, | OS, | MG63 |
| 5334- | TFdiG, | Theaflavin inhibits the malignant phenotype of human anaplastic thyroid cancer 8305C cells by regulating lipid metabolism via PI3K/AKT signaling |
| - | in-vitro, | Thyroid, | 8505C |
| 113- | TQ, | Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer |
| - | vitro+vivo, | Pca, | C4-2B |
| 1019- | TQ, | Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation |
| - | vitro+vivo, | CRC, | LoVo |
| 3411- | TQ, | Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone |
| - | Review, | Var, | NA |
| 3408- | TQ, | Thymoquinone: A small molecule from nature with high therapeutic potential |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3401- | TQ, | Molecular mechanisms and signaling pathways of black cumin (Nigella sativa) and its active constituent, thymoquinone: a review |
| - | Review, | Var, | NA |
| 3397- | TQ, | Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 3425- | TQ, | Advances in research on the relationship between thymoquinone and pancreatic cancer |
| 3431- | TQ, | PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 3421- | TQ, | Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer |
| - | Analysis, | Nor, | NA | - | in-vivo, | Nor, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HaCaT |
| 3417- | TQ, | Antiproliferative Effects of Thymoquinone in MCF-7 Breast and HepG2 Liver Cancer Cells: Possible Role of Ceramide and ER Stress |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Liver, | HepG2 |
| 3416- | TQ, | Thymoquinone induces apoptosis in bladder cancer cell via endoplasmic reticulum stress-dependent mitochondrial pathway |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | in-vitro, | Bladder, | 253J | - | in-vitro, | Nor, | SV-HUC-1 |
| 3559- | TQ, | Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3571- | TQ, | The Role of Thymoquinone in Inflammatory Response in Chronic Diseases |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA |
| 1308- | TQ, | Thymoquinone induces apoptosis via targeting the Bax/BAD and Bcl-2 pathway in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 2121- | TQ, | Thymoquinone Inhibits Tumor Growth and Induces Apoptosis in a Breast Cancer Xenograft Mouse Model: The Role of p38 MAPK and ROS |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 2119- | TQ, | Dual properties of Nigella Sativa: anti-oxidant and pro-oxidant |
| - | Review, | Var, | NA |
| 2097- | TQ, | Crude extract of Nigella sativa inhibits proliferation and induces apoptosis in human cervical carcinoma HeLa cells |
| - | in-vitro, | Cerv, | HeLa |
| 2099- | TQ, | Cisplatin, | Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo |
| - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H146 | - | in-vivo, | NA, | NA |
| 2104- | TQ, | The Potential Role of Nigella sativa Seed Oil as Epigenetic Therapy of Cancer |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Cerv, | HeLa |
| 2105- | TQ, | Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation |
| - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | Hs766t | - | in-vivo, | NA, | NA |
| 1928- | TQ, | Thymoquinone Crosstalks with DR5 to Sensitize TRAIL Resistance and Stimulate ROS-Mediated Cancer Apoptosis |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1929- | TQ, | Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells |
| - | in-vitro, | Bladder, | 5637 | - | in-vitro, | Bladder, | T24/HTB-9 |
| 1930- | TQ, | Therapeutic implications and clinical manifestations of thymoquinone |
| - | Review, | Var, | NA |
| 1936- | TQ, | Thymoquinone induces apoptosis and increase ROS in ovarian cancer cell line |
| - | in-vitro, | Ovarian, | CaOV3 | - | in-vitro, | Nor, | WRL68 |
| 3747- | TTT, | Tumor treating induced fields: a new treatment option for patients with glioblastoma |
| - | in-vitro, | GBM, | U87MG |
| 1020- | UA, | Root Bark of Morus alba L. and Its Bioactive Ingredient, Ursolic Acid, Suppress the Proliferation of Multiple Myeloma Cells by Inhibiting Wnt/β-Catenin Pathway |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 5019- | UA, | Ursolic acid in colorectal cancer: mechanisms, current status, challenges, and future research directions |
| - | Review, | Var, | NA |
| 5021- | UA, | Anticancer effect of ursolic acid via mitochondria-dependent pathways |
| - | Review, | Var, | NA |
| 5022- | UA, | Ursolic Acid’s Alluring Journey: One Triterpenoid vs. Cancer Hallmarks |
| - | Review, | Var, | NA |
| 4856- | Uro, | Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro |
| - | in-vitro, | NPC, | CNE1 | - | in-vitro, | NPC, | CNE2 |
| 4833- | Uro, | Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
| 4837- | Uro, | Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review |
| - | Review, | Var, | NA |
| 4840- | Uro, | Urolithin A: A promising selective estrogen receptor modulator and 27-hydroxycholesterol attenuator in breast cancer |
| - | vitro+vivo, | BC, | NA |
| 4841- | Uro, | Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53-p21 proteins and reactive oxygen species production in colorectal cancer cells |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
| 4842- | Uro, | Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | 4T1 |
| 4843- | Uro, | The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide |
| - | in-vitro, | Pca, | LNCaP |
| 4847- | Uro, | Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620 colorectal cancer cells |
| - | in-vitro, | CRC, | SW-620 |
| 4849- | Uro, | Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway |
| - | vitro+vivo, | GC, | NA |
| 4853- | Uro, | Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer |
| - | vitro+vivo, | PC, | MIA PaCa-2 | - | in-vitro, | NA, | PANC1 |
| 3143- | VitC, | ATO, | Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis |
| - | in-vitro, | OS, | NA |
| 3133- | VitC, | Vitamin C supplementation had no side effect in non-cancer, but had anticancer properties in ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA |
| 115- | VitD3, | Vitamin D3 Inhibits Hedgehog Signaling and Proliferation in Murine Basal Cell Carcinomas |
| - | in-vivo, | RCC, | NA | - | in-vivo, | BCC, | NA |
| 1739- | VitD3, | Effect of Vitamin D3 Supplements on Development of Advanced Cancer |
| - | Trial, | Var, | NA |
| 1816- | VitK2, | Role of Vitamin K in Selected Malignant Neoplasms in Women |
| - | Review, | Var, | NA |
| 1823- | VitK2, | VitK3, | Vitamins K2, K3 and K5 exert antitumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells |
| - | in-vitro, | CRC, | NA | - | in-vivo, | NA, | NA |
| 1829- | VitK2, | Vitamin K: New insights related to senescence and cancer metastasis |
| - | Review, | Var, | NA |
| 1833- | VitK2, | Divergent effects of vitamins K1 and K2 on triple negative breast cancer cells |
| - | in-vitro, | BC, | HS587T | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | SUM159 |
| 1213- | VitK2, | Vitamin K2 Inhibits Hepatocellular Carcinoma Cell Proliferation by Binding to 17β-Hydroxysteroid Dehydrogenase 4 |
| - | in-vitro, | HCC, | HepG2 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:327 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid